Abstract
The aim of this study was to investigate the effects of ALC treatment on cognitive functions in patients with severe hepatic encephalopathy. This was a randomized, double-blind, placebo-controlled study. 61 patients with severe hepatic encephalopathy were recruited to the study. The 2 groups received either 2 g ALC twice a day (n = 30) or placebo (n = 30) for 90 days. Clinical and laboratory assessment, psychometric tests and automated electroencephalogram (EEG) analysis were performed for all patients. At the end of the study period, between the 2 groups we observed a significant difference in Everyday Memory Questionnaire −23.9 vs 4.4 (p < 0.001), Logical Memory (Paragraph recall) test 22.3 vs 0.7 (p < 0.001), Trail Making Test A −7.5 vs −2.6 (p < 0.001), Trail Making Test B −10.5 vs −3.1 (p < 0.001), Controlled Oral Word Association Test 4.2 vs 0.5 (p < 0.001), Hooper test 2.6 vs 0.1 (p < 0.05), Judgement of line orientation 2.8 vs 0.3 (p < 0.001), Digit Cancellation time −24.5 vs −2.4 (p < 0.001), NH +4 30.5 vs 13.5 (p < 0.001), prothrombin time 2 vs 2.4 (p < 0.05), alanine transaminase −10.7 vs −13.6 (p < 0.001). 88% of patients treated with ALC vs 72% of patients treated with placebo showed a significant improvement in EEG. The improvement of cognitive deficits, the reduction of ammonia, and the modification of EEG in patients treated with ALC suggest that ALC could represent a new tool in the treatment of severe hepatic encephalopathy.
Similar content being viewed by others
References
Beal MF (1993) Neurochemical aspects of aging in primates. Neurobiol Aging 14:707–709. doi:10.1016/0197-4580(93)90080-U
Bélanger M, Desjardins P, Chatauret N, Butterworth RF (2002) Loss of expression of glial fibrillary acidic protein in acute hyperammonemia. Neurochem Int 41:155–160. doi:10.1016/S0197-0186(02)00037-2
Benton AL (1994) Neuropsychological assessment. Annu Rev Psychol 45:1–23. doi:10.1146/annurev.ps.45.020194.000245
Binienda ZK (2003) Neuroprotective effects of L-carnitine in induced mitochondrial dysfunction. Ann N Y Acad Sci 993:289–295. doi:10.1111/j.1749-6632.2003.tb07536.x
Bremer J (1983) Carnitine-metabolism and functions. Physiol Rev 63:1420–1480, PMid:6361812
Brooks JO 3rd, Yesavage JA, Carta A, Bravi D (1998) Acetyl L-carnitine slows decline in younger patients with Alzheimer's disease: a reanalysis of a double-blind, placebo-controlled study using the trilinear approach. Int Psychogeriatr 10:193–203. doi:10.1017/S1041610298005304
Butterworth RF (2001) Neurotransmitter dysfunction in hepatic encephalopathy: new approaches and new findings. Metab Brain Dis 16:55–65. doi:10.1023/A:1011614528751
Butterworth RF (2002) Pathophysiology of hepatic encephalopathy: a new look at ammonia. Metab Brain Dis 17:221–227. doi:10.1023/A:1021989230535
Butterworth RF, Giguère JF, Michaud J, Lavoie J, Layrargues GP (1987) Ammonia: key factor in the pathogenesis of hepatic encephalopathy. Neurochem Pathol 6:1–12. doi:10.1007/BF02833598
Da Fonseca-Wollheim F (1973) Direkte plasmaammoniakbestimmung ohne Enteiweissung. Z Klin Chem Biochem 11:426–431
Desjardins P, Todd KG, Hazell AS, Butterworth RF (1999) Increased "peripheral-type" benzodiazepine receptor sites and mRNA in thalamus of thiamine-deficient rats. Neurochem Int 35:363–369. doi:10.1016/S0197-0186(99)00082-0
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486–2497. doi:10.1001/jama.285.19.2486
Felipo V, Miñana MD, Cabedo H, Grisolía S (1994) L-carnitine increases the affinity of glutamate for quisqualate receptors and prevents glutamate neurotoxicity. Neurochem Res 19:373–377. doi:10.1007/BF00971588
Felipo V, Hermenegildo C, Montoliu C, Llansola M, Miñana MD (1998) Neurotoxicity of ammonia and glutamate: molecular mechanisms and prevention. Neurotoxicology 19:675–681, PMid:9745928
Flanagan JL, Simmons PA, Vehige J, Willcox MD, Garrett Q (2010) Role of carnitine in disease. Nutr Metab (Lond) 7:30. doi:10.1186/1743-7075-7-30
Folstein MF, Folstein SE, McHugh PR (1975) “Mini Mental State”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–198. doi:10.1016/0022-3956(75)90026-6
Franklin GM, Heaton RK, Nelson LM, Filley CM, Seibert C (1988) Correlation of neuropsychological and MRI findings in chronic/progressive multiple sclerosis. Neurology 38:1826–1829, PMid:3194059
Gregorios JB, Mozes LW, Norenberg MD (1985) Morphologic effects of ammonia on primary astrocyte cultures. II. Electron microscopic studies. J Neuropathol Exp Neurol 44:404–414. doi:10.1097/00005072-198507000-00004
Hagen TM, Liu J, Lykkesfeldt J, Wehr CM, Ingersoll RT, Vinarsky V, Bartholomew JC, Ames BN (2002) Feeding acetyl-L-carnitine and lipoic acid to old rats significantly improves metabolic function while decreasing oxidative stress. Proc Natl Acad Sci U S A 99:1870–1875. doi:10.1073/pnas.261708898
Harper C, Butterworth RF (1997) Nutritional and metabolic disorders. In: Lantos P, Graham D (eds) Greenfield's neuropathology, 6th edn. Edward Arnold, Cambridge, pp 601–655
Häussinger D, Schliess F (2008) Pathogenetic mechanisms of hepatic encephalopathy. Gut 57:1156–1165. doi:10.1136/gut.2007.122176
Häussinger D, Kircheis G, Fischer R, Schliess F, vom Dahl S (2000) Hepatic encephalopathy in chronic liver disease: a clinical manifestation of astrocyte swelling and low-grade cerebral edema? J Hepatol 32:1035–1038. doi:10.1016/S0168-8278(00)80110-5
Hinerfeld D, Traini MD, Weinberger RP, Cochran B, Doctrow SR, Harry J, Melov S (2004) Endogenous mitochondrial oxidative stress: neurodegeneration, proteomic analysis, specific respiratory chain defects, and efficacious antioxidant therapy in superoxide dismutase 2 null mice. J Neurochem 88:657–667. doi:10.1046/j.1471-4159.2003.02195.x
Hooper HE (1983) Hooper visual organization test. WPS
Jover R, Rodrigo R, Felipo V, Insausti R, Sáez-Valero J, García-Ayllón MS, Suárez I, Candela A, Compañ A, Esteban A, Cauli O, Ausó E, Rodríguez E, Gutiérrez A, Girona E, Erceg S, Berbel P, Pérez-Mateo M (2006) Brain edema and inflammatory activation in bile duct ligated rats with diet-induced hyperammonemia: a model of hepatic encephalopathy in cirrhosis. Hepatology 43:1257–1266. doi:10.1002/hep.21180
Malaguarnera M, Pistone G, Astuto M, Dell'Arte S, Finocchiaro G, Lo Giudice E, Pennisi G (2003) L-Carnitine in the treatment of mild or moderate hepatic encephalopathy. Dig Dis 21(3):271–275. doi:10.1159/000073347 PMid:14571103
Malaguarnera M, Pistone G, Elvira R, Leotta C, Scarpello L, Liborio R (2005) Effects of L-carnitine in patients with hepatic encephalopathy. World J Gastroenterol 11(45):7197–7202
Malaguarnera M, Pistone G, Astuto M, Vecchio I, Raffaele R, Lo Giudice E, Rampello L (2006) Effects of L-acetylcarnitine on cirrhotic patients with hepatic coma: randomized double-blind, placebo-controlled trial. Dig Dis Sci 51:2242–2247. doi:10.1007/s10620-006-9187-0, PMid:17080254
Malaguarnera M, Cammalleri L, Gargante MP, Vacante M, Colonna V, Motta M (2007) L-Carnitine treatment reduces severity of physical and mental fatigue and increases cognitive functions in centenarians: a randomized and controlled clinical trial. Am J Clin Nutr 86(6):1738–1744
Malaguarnera M, Gargante MP, Cristaldi E, Vacante M, Risino C, Cammalleri L, Pennisi G, Rampello L (2008) Acetyl-L-carnitine treatment in minimal hepatic encephalopathy. Dig Dis Sci 53:3018–3025. doi:10.1007/s10620-008-0238-6
Malaguarnera M, Bella R, Vacante M, Giordano M, Malaguarnera G, Gargante MP, Motta M, Mistretta A, Rampello L, Pennisi G (2011a) Acetyl-L-carnitine reduces depression and improves quality of life in patients with minimal hepatic encephalopathy. Scand J Gastroenterol 46(6):750–759. doi:10.3109/00365521.2011.565067 PMid:21443422
Malaguarnera M, Vacante M, Giordano M, Pennisi G, Bella R, Rampello L, Malaguarnera M, Li Volti G, Galvano F (2011b) Oral acetyl-L-carnitine therapy reduces fatigue in overt hepatic encephalopathy: a randomized, double-blind, placebo-controlled study. Am J Clin Nutr 93(4):799–808. doi:10.3945/ajcn.110.007393 PMid:21310833
Matsuoka M, Igisu H (1993) Comparison of the effects of L-carnitine, D-carnitine and acetyl-L-carnitine on the neurotoxicity of ammonia. Biochem Pharmacol 46:159–164. doi:10.1016/0006-2952(93)90360-9
Montgomery SA, Thal LJ, Amrein R (2003) Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer's disease. Int Clin Psychopharmacol 18:61–71. doi:10.1097/00004850-200303000-00001
Neary JT, Norenberg LO, Gutierrez MP, Norenberg MD (1987) Hyperammonemia causes altered protein phosphorylation in astrocytes. Brain Res 437:161–164. doi:10.1016/0006-8993(87)91538-1
Peluso G, Barbarisi A, Savica V, Reda E, Nicolai R, Benatti P, Calvani M (2000) Carnitine: an osmolyte that plays a metabolic role. J Cell Biochem 80:1–10. doi:10.1002/1097-4644(20010101)80:1<1::AID-JCB10>3.0.CO;2-W
Pettegrew JW, Levine J, McClure RJ (2000) Acetyl-L-carnitine physical-chemical, metabolic, and therapeutic properties: relevance for its mode of action in Alzheimer’s disease and geriatric depression. Mol Psychiatry 5:616–632. doi:10.1038/sj.mp.4000805
Poveda MJ, Bernabeu A, Concepción L, Roa E, de Madaria E, Zapater P, Pérez-Mateo M, Jover R (2010) Brain edema dynamics in patients with overt hepatic encephalopathy A magnetic resonance imaging study. NeuroImage 52:481–487. doi:10.1016/j.neuroimage.2010.04.260
Pugh RN, Murray-Lyon IM, Dawson JL, Petroni MC, Williams R (1973) Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 60:646–649. doi:10.1002/bjs.1800600817
Qureshi K, Rao KV, Qureshi IA (1998) Differential inhibition by hyperammonemia of the electron transport chain enzymes in synaptosomes and non-synaptic mitochondria in ornithine transcarbamylase-deficient spf-mice: restoration by acetyl-L-carnitine. Neurochem Res 23:855–861. doi:10.1023/A:1022406911604
Rao KV, Mawal YR, Qureshi IA (1997) Progressive decrease of cerebral cytochrome C oxidase activity in sparse-fur mice: role of acetyl-L-carnitine in restoring the ammonia-induced cerebral energy depletion. Neurosci Lett 224:83–86. doi:10.1016/S0304-3940(97)13476-0
Ratnakumari L, Qureshi IA, Butterworth RF (1993) Effect of L-carnitine on cerebral and hepatic energy metabolites in congenitally hyperammonemic sparse-fur mice and its role during benzoate therapy. Metabolism 42:1039–1046. doi:10.1016/0026-0495(93)90020-O
Reitan RM, Wolfson D (1993) The Halstead-Reitan: neuropsychological test battery: theory and clinical interpretation. Neuropsychology Press, Tucson
Spagnoli A, Lucca U, Menasce G, Bandera L, Cizza G, Forloni G, Tettamanti M, Frattura L, Tiraboschi P, Comelli M et al (1991) Long-term acetyl-L-carnitine treatment in Alzheimer's disease. Neurology 41:1726–1732
Sunderland A, Harris JE, Baddeley AD (1983) Do laboratory tests predict A neuropsychological study. J Verbal Learning Verbal Behav 22:341–357. doi:10.1016/S0022-5371(83)90229-3
Thal LJ, Calvani M, Amato A, Carta A (2000) A 1-year controlled trial of acetyl-l-carnitine in early-onset AD. Neurology 55:805–810
Van Der Rijt C, Schalm SW (1985) Quantitative EEG analysis and survival in liver disease. Electroencephalogr Clin Neurophysiol 61:502–504. doi:10.1016/0013-4694(85)90968-X
Virmani A, Binienda Z (2004) Role of carnitine esters in brain neuropathology. Mol Aspects Med 25:533–549. doi:10.1016/j.mam.2004.06.003
Voigt M, Conn H (1995) Hepatic encephalopathy. In: Robson SC, Trey C, Kirsch RE (eds) Diagnosis and management of liver disease. Chapman & Hall, London, pp 140–147, Chapter 13
Wechsler D (1945) A standardized Memory Scale for Clinical use. J Psychol 87:95
World Medical Association Declaration of Helsinki (1997) Recommendations guiding physicians in biomedical research involving human subjects. JAMA 277:925–926. doi:10.1001/jama.277.11.925
Wright G, Jalan R (2007) Ammonia and inflammation in the pathogenesis of hepatic encephalopathy: Pandora's box? Hepatology 46:291–294. doi:10.1002/hep.21843
Conflicts of interest
The authors disclose no conflicts.
Funding
This clinical trial was supported by a grant from MURST (Ministero dell’Università e Ricerca Scientifica e Tecnologica).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Malaguarnera, M., Vacante, M., Motta, M. et al. Acetyl-L-carnitine improves cognitive functions in severe hepatic encephalopathy: a randomized and controlled clinical trial. Metab Brain Dis 26, 281–289 (2011). https://doi.org/10.1007/s11011-011-9260-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11011-011-9260-z